PF-Atlas › Clinical Trials › NCT02503657

Safety, Tolerability, and Efficacy of MN-001 in Patients With Idiopathic Pulmonary Fibrosis

MN-001 · Novel Therapy · Phase 2

Registry ID
NCT02503657
Phase
Phase 2
Status
Completed
Drug / intervention
MN-001
Mechanism
Novel Therapy
Sponsor
MediciNova
Start
2016-03-09
Enrollment
15
Locations
1

About this trial

This is a randomized, placebo-controlled, double-blind, 6-month study followed by a 6-month open-label extension phase to evaluate the efficacy, safety, and tolerability of MN-001 in patients diagnosed with moderate to severe idiopathic pulmonary fibrosis (IPF). Participants were randomly assigned to receive MN-001 or matching placebo twice daily over a 26-week period. A total of 15 participants were enrolled.

View NCT02503657 on ClinicalTrials.gov →

Explore related

All MN-001 trialsNovel Therapy mechanismAll IPF trials
Medical disclaimer. This page summarizes public trial data for NCT02503657 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.